Editorial
|
|
|
|
|
"Regulatory capture" and other forms of institutionalised corruption harm patients' interest
|
|
|
|
New Products
|
|
|
|
|
Unnecessary bronchial irritation
|
|
|
|
|
|
|
|
|
|
|
|
Acute myeloid leukaemia: no progress
|
|
|
|
|
|
|
|
|
|
|
|
Promising for some women with metastatic breast cancer, but more assessment needed
|
|
|
|
|
|
Adverse Effects
|
|
|
|
|
Identifying problems in a timely manner is essential
|
|
|
|
|
|
|
|
|
|
More and more drugs implicated
|
|
|
|
|
|
|
|
|
|
|
|
Studies confirm increased risk
|
|
|
|
|
|
|
|
|
|
|
|
Losartan or valsartan are the preferred sartans
|
|
|
|
Reviews
|
|
|
|
|
Some advances, but too many new treatments with an inadequately assessed harm-benefit balance
|
|
|
|
|
|
|
|
|
|
Outlook
|
|
|
|
|
Marketing authorisations still granted despite inadequate data
|
|
|
|
|
|
|
|
|
|
|
|
Risk of medication errors
|
|
|
|
|
|